Langlois, Marie-France

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

Obesity in adults: a clinical practice guideline

Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal

Obesity, Physical Activity, DietObesity and Health Practices

Cited by 1,506

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 638

Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study

Sharma, A. M., Bélanger, A., Carson, V., Krah, J., Langlois, M., Lawlor, D., Lepage, S., Liu, A., Macklin, D. A., MacKay, N., et al. (2019) · Clinical Obesity

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 86

L‐T3 preparation for whole‐body scintigraphy: a randomized‐controlled trial

Leboeuf, R., Perron, P., Carpentier, A. C., Verreault, J., & Langlois, M. (2007) · Clinical Endocrinology

Thyroid Cancer Diagnosis and TreatmentThyroid Disorders and Treatments

Cited by 38

In vitro effect of TRIAC on resistance to thyroid hormone receptor mutants: potential basis for therapy

Messier, N., Laflamme, L., Hamann, G., & Langlois, M. F. (2001) · Molecular and Cellular Endocrinology

Thyroid Disorders and TreatmentsEstrogen and related hormone effects

Cited by 31